UNSPSC 51373450: Codeine/phenylephrine/potassium guaiacolsulfonate/promethazine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373450 Codeine/phenylephrine/potassium guaiacolsulfonate/promethazine is a Commodity code that does not align with recent state and local procurement activity posted under this classification. The two posted opportunities—Seminole County's procurement of naloxone and drug deactivation systems, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—target pharmaceutical supply chains and emergency medical products that fall outside the specific branded cough syrup formulation named in the code. State and local governments do source pharmaceuticals through cooperative purchasing vehicles and direct RFPs, but the recent opportunities show no demand for the particular active-ingredient combination (codeine, phenylephrine, potassium guaiacolsulfonate, and promethazine) that defines this Commodity code.

The geographic spread of recent activity covers Florida (Seminole County) and Minnesota (MMCAP, which includes participating states and Oregon), but neither procurement explicitly solicits the specific formulation in this code. The Seminole County IFB (due July 26, 2023) targets naloxone for overdose response and drug deactivation systems; the MMCAP RFP (due March 26, 2026) establishes multi-vendor contracts for generic pharmaceuticals through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) with awards effective July 1, 2026. Both solicitations emphasize compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements. State and local agencies pursuing this Commodity code should recognize limited recent market activity under this specific classification and consider broader pharmaceutical-supply Family and Class codes to identify actual procurement volume.